Information Provided By: 
Fly News Breaks for July 13, 2018
ZGNX
Jul 13, 2018 | 08:00 EDT
Leerink analyst Geoffrey Porges raised his price target for Zogenix to $92 from $52 after the company reports topline data from its second Dravet phase 3 study yesterday, stating that the data appear to represent a "best case scenario" given they approximate study one's strong efficacy and show clean cardiac safety. Porges, who thinks yesterday's 21% advance in the shares was a "reasonable reflection of the confirmation of the drug's profile," maintains an Outperform rating on Zogenix shares.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
